Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: Implications for therapy of EBV associated tumors

Cancer Biology and Therapy

Volumn 8, Issue 11, 2009, Pages 987-995

  Chen, Changguo ^a,b   Li, Dan ^a,c   Guo, Ning ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NAVY GENERAL HOSPITAL   (China)

^c 306 HOSPITAL OF PLA   (China)

Author keywords

Cell cycle progression; EBV; Herpesvirus; Immediate early protein; Lytic cycle; Transcription; Tumor; Zta

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; AZACITIDINE; BUTYRIC ACID; CISPLATIN; EARLY GROWTH RESPONSE FACTOR 1; GANCICLOVIR; IMMEDIATE EARLY PROTEIN BZLF1; INTERLEUKIN 10; INTERLEUKIN 8; MYC PROTEIN; NUCLEOSIDE ANALOG; PROTEIN C FOS; PROTEIN C JUN;

ANTIVIRAL THERAPY; BURKITT LYMPHOMA; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DEATH; DRUG TARGETING; EPSTEIN BARR VIRUS; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOMODULATION; LYMPHOMA CELL; MEMORY CELL; REVIEW; TUMOR CELL DESTRUCTION; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REACTIVATION;

EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; TRANS-ACTIVATORS; VIRAL PROTEINS;

EID: 68049125061     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.11.8369     Document Type: Review

References (106)

1. Hepeng J, Zeng Yi. A controversial bid to thwart the 'Cantonese cancer.' Science 2008; 321:1154-5.
2. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 2003; 100:14269-74.
3. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989; 320:502-6.
4. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 1994; 21:376-81.
5. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 1992; 3:297-307.
6. McClain KL, Leach CT, Jenson HB, Joshi VV, Pollock BH, Parmley RT, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995; 332:12-8.
7. MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338:969-73.
8. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990; 335:128-30.
9. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992; 140:769-74.
10. Gulley ML, Pulitzer DR, Eagan PA, Schneider BG. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996; 27:20-7.
11. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999; 91:1376-81.
12. Sugawara Y, Makuuchi M, Takada K. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand J Gastroenterol 2000; 35:981-4.
13. Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren WH, De Matteo E, et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 2002; 62:4876-8.
14. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89:98-103.
15. Papesch M, Watkins R. Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol Allied Sci 2001; 26:3-8.
16. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343:481-92.
17. Li QX, Young LS, Niedobitek G, Dawson CW, Birkenbach M, Wang F, et al. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 1992; 356:347-50.
18. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310:1225-30.
19. Jenkins PJ, Binne UK, Farrell PJ. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 2000; 74:710-20.
20. Adams A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987; 61:1743-6.
21. Kirchmaier AL, Sugden B. Plasmid maintenance of derivatives of oriP of Epstein-Barr virus. J Virol 1995; 69:1280-3.
22. Flemington E, Speck SH. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 1990; 64:1227-32.
23. Hardwick JM, Lieberman PM, Hayward SD. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 1988; 62:2274-84.
24. Quinlivan EB, Holley-Guthrie EA, Norris M, Gutsch D, Bachenheimer SL, Kenney SC. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res 1993; 21:1999-2007.
25. Fixman ED, Hayward GS, Hayward SD. Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol 1995; 69:2998-3006.
26. Fixman ED, Hayward GS, Hayward SD. Trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J Virol 1992; 66:5030-9.
27. Schepers A, Pich D, Hammerschmidt W. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J 1993; 12:3921-9.
28. Takada K, Ono Y. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 1989; 63:445-9.
29. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310:207-11.
30. Marshall WL, Yim C, Gustafson E, Graf T, Sage DR, Hanify K, et al. Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J Virol 1999; 73:5181-5.
31. Zhang Q, Holley-Guthrie E, Ge JQ, Dorsky D, Kenney S. The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt. Virology 1997; 230:22-34.
32. Urier G, Buisson M, Chambard P, Sergeant A. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J 1989; 8:1447-53.
33. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. Epstein-Barr virus BZLF1 transactivator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 1989; 8:127-32.
34. Kenney S, Holley-Guthrie E, Mar EC, Smith M. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J Virol 1989; 63:3878-83.
35. Lieberman PM, Hardwick JM, Hayward SD. Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J Virol 1989; 63:3040-50.
36. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol 1990; 64:1143-55.
37. Chang YN, Dong DL, Hayward GS, Hayward SD. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J Virol 1990; 64:3358-69.
38. Wang P, Day L, Dheekollu J, Lieberman PM. A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication. J Virol 2005; 79:13298-309.
39. Flemington E, Speck SH. Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues. Proc Natl Acad Sci USA 1990; 87:9459-63.
40. Kouzarides T, Packham G, Cook A, Farrell PJ. The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 1991; 6:195-204.
41. Miller G, Himmelfarb H, Heston L, Countryman J, Gradoville L, Baumann R, et al. Comparing regions of the Epstein-Barr virus ZEBRA protein which function as transcriptional activating sequences in Saccharomyces cerevisiae and in B-cells. J Virol 1993; 67:7472-81.
42. Flemington EK, Borras AM, Lytle JP, Speck SH. Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain. J Virol 1992; 66:922-9.
43. Chi T, Carey M. The ZEBRA activation domain: modular organization and mechanism of action. Mol Cell Biol 1993; 13:7045-55.
44. Kolman JL, Taylor N, Marshak DR, Miller G. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation. Proc Natl Acad Sci USA 1993; 90:10115-9.
45. Packham G, Economou A, Rooney CM, Rowe DT, Farrell PJ. Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol 1990; 64:2110-6.
46. Countryman J, Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci USA 1985; 82:4085-9.
47. Takada K, Shimizu N, Sakuma S, Ono Y. Trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol 1986; 57:1016-22.
48. Adamson AL, Kenney S. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol 1999; 73:6551-8.
49. Gao Z, Krithivas A, Finan JE, Semmes OJ, Zhou S, Wang Y, et al. The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol 1998; 72:8559-67.
50. Baumann M, Feederle R, Kremmer E, Hammerschmidt W. Cellular transcription factors recruit viral replication proteins to activate the Epstein-Barr virus origin of lytic DNA replication, oriLyt. EMBO J 1999; 18:6095-105.
51. Zhang Q, Hong Y, Dorsky D, Holley-Guthrie E, Zalani S, Elshiekh NA, et al. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: effects on EBV transcription and lytic replication. J Virol 1996; 70:5131-42.
52. Ernberg I, Falk K, Minarovits J, Busson P, Tursz T, Masucci MG, et al. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 1989; 70:2989-3002.
53. Paulson EJ, Speck SH. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol 1999; 73:9959-68.
54. Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997; 90:4480-4.
55. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol 2005; 79:7338-48.
56. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 2004; 36:1099-104.
57. El-Guindy AS, Miller G. Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol 2004; 78:7634-44.
58. Adamson AL, Kenney SC. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 1998; 251:187-97.
59. Francis A, Ragoczy T, Gradoville L, Heston L, El-Guindy A, Endo Y, et al. Amino acid substitutions reveal distinct functions of serine 186 of the ZEBRA protein in activation of early lytic cycle genes and synergy with the Epstein-Barr virus R transactivator. J Virol 1999; 73:4543-51.
60. Francis AL, Gradoville L, Miller G. Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. J Virol 1997; 71:3054-61.
61. Bannister AJ, Cook A, Kouzarides T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene 1991; 6:1243-50.
62. Sternsdorf T, Jensen K, Reich B, Will H. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization and modification by small ubiquitin-like modifiers. J Biol Chem 1999; 274:12555-66.
63. Adamson AL, Kenney S. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 2001; 75:2388-99.
64. Lieberman PM, Berk AJ. In vitro transcriptional activation, dimerization and DNA-binding specificity of the Epstein-Barr virus Zta protein. J Virol 1990; 64:2560-8.
65. Flemington E, Speck SH. Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos. J Virol 1990; 64:4549-52.
66. Sato H, Takeshita H, Furukawa M, Seiki M. Epstein-Barr virus BZLF1 transactivator is a negative regulator of Jun. J Virol 1992; 66:4732-6.
67. Gutsch DE, Holley-Guthrie EA, Zhang Q, Stein B, Blanar MA, Baldwin AS, et al. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NFkappaB. Mol Cell Biol 1994; 14:1939-48.
68. Jones RJ, Dickerson S, Bhende PM, Delecluse HJ, Kenney SC. Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9. J Biol Chem 2007; 282:8317-24.
69. Sista ND, Barry C, Sampson K, Pagano J. Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RAR alpha and RXR alpha. Nucleic Acids Res 1995; 23:1729-36.
70. Lieberman PM, Berk AJ. The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev 1991; 5:2441-54.
71. Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 1994; 14:1929-38.
72. Cayrol C, Flemington EK. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGFbeta igh3) and TGFbeta 1. J Virol 1995; 69:4206-12.
73. di Renzo L, Altiok A, Klein G, Klein E. Endogenous TGFbeta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int J Cancer 1994; 57:914-9.
74. Skonier J, Bennett K, Rothwell V, Kosowski S, Plowman G, Wallace P, et al. beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 1994; 13:571-84.
75. Paralkar VM, Vukicevic S, Reddi AH. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev Biol 1991; 143:303-8.
76. Hsu M, Wu SY, Chang SS, Su IJ, Tsai CH, Lai SJ, et al. Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 2008; 82:3679-88.
77. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151:1105-13.
78. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990; 248:1230-4.
79. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
80. Miyazaki I, Cheung RK, Dosch HM. Viral interleukin 10 is critical for the induction of B-cell growth transformation by Epstein-Barr virus. J Exp Med 1993; 178:439-47.
81. Swaminathan S, Hesselton R, Sullivan J, Kieff E. Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. J Virol 1993; 67:7406-13.
82. Sairenji T, Ohnishi E, Inouye S, Kurata T. Induction of interleukin-10 on activation of Epstein-Barr virus in EBV-infected B-cell lines. Viral Immunol 1998; 11:221-31.
83. Mahot S, Sergeant A, Drouet E, Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen Virol 2003; 84:965-74.
84. Keating S, Prince S, Jones M, Rowe M. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol 2002; 76:8179-88.
85. Li D, Qian L, Chen C, Shi M, Yu M, Hu M, et al. Downregulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. J Immunol 2009; 182:1799-809.
86. Giot JF, Mikaelian I, Buisson M, Manet E, Joab I, Nicolas JC, et al. Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res 1991; 19:1251-8.
87. Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC. Inhibition of IFNgamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001; 15:787-99.
88. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96:41-101.
89. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 2002; 76:12503-12.
90. Cayrol C, Flemington EK. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 1996; 15:2748-59.
91. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 2005; 15:3-15.
92. Mauser A, Holley-Guthrie E, Zanation A, Yarborough W, Kaufmann W, Klingelhutz A, et al. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. J Virol 2002; 76:12543-52.
93. Chang Y, Lee HH, Chen YT, Lu J, Wu SY, Chen CW, et al. Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J Virol 2006; 80:7748-55.
94. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 1999; 73:4481-4.
95. Lin Z, Yin Q, Flemington E. Identification of a negative regulatory element in the Epstein-Barr virus Zta transactivation domain that is regulated by the cell cycle control factors c-Myc and E2F1. J Virol 2004; 78:11962-71.
96. Westphal EM, Mauser A, Swenson J, Davis MG, Talarico CL, Kenney SC. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res 1999; 59:1485-91.
97. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001; 45:2082-91.
98. Lin JC, Nelson DJ, Lambe CU, Choi EI. Metabolic activation of 9 ([2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus. J Virol 1986; 60:569-73.
99. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004; 78:1893-902.
100. Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, et al. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 2002; 76:10951-9.
101. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002; 62:1920-6.
102. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000; 60:5781-8.
103. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004; 22:1373-81.
104. Shimizu N, Takada K. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence. J Virol 1993; 67:3240-5.
105. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 1984; 33:27-32.
106. Israel BF, Pickles RJ, Segal DM, Gerard RD, Kenney SC. Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody. J Virol 2001; 75:5215-21.